Key Points
- Insider Brendan Buckley sold 2,017,000 shares on April 24 at an average price of GBX 9, generating a total of £181,530.
- The company reported a loss of GBX (0.87) per share last quarter with a negative return on equity (-14.65%) and net margin (-12.48%), while revenue was GBX 4,677 million and the market cap is £53.35 million.
- Analysts are broadly positive with two Buys and one Hold, an average rating of Moderate Buy and a consensus target price of GBX 15.
hVIVO plc (LON:HVO - Get Free Report) insider Brendan Buckley sold 2,017,000 shares of the stock in a transaction that occurred on Friday, April 24th. The stock was sold at an average price of GBX 9, for a total transaction of £181,530.
hVIVO Stock Up 2.0%
HVO stock opened at GBX 7.75 on Friday. hVIVO plc has a 12-month low of GBX 4.31 and a 12-month high of GBX 19.50. The company has a quick ratio of 1.16, a current ratio of 1.63 and a debt-to-equity ratio of 38.75. The company has a market cap of £53.35 million, a price-to-earnings ratio of 10.06 and a beta of 1.67. The company has a 50 day moving average of GBX 7.94 and a two-hundred day moving average of GBX 6.88.
hVIVO (LON:HVO - Get Free Report) last released its earnings results on Wednesday, April 15th. The company reported GBX (0.87) earnings per share (EPS) for the quarter. hVIVO had a negative return on equity of 14.65% and a negative net margin of 12.48%.The company had revenue of GBX 4,677 million during the quarter. On average, equities analysts anticipate that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on HVO. Shore Capital Group reiterated a "buy" rating on shares of hVIVO in a report on Wednesday. Stifel Nicolaus reiterated a "hold" rating and issued a GBX 10 price objective on shares of hVIVO in a report on Wednesday, April 15th. Two equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of GBX 15.
View Our Latest Analysis on hVIVO
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
